Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.48 |
| ▸ | INSR | P06213 | 5/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.35 |
| ▸ | STK17B | O94768 | 1/20 | 0.34 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CDK7 | P50613 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4289850 | 0.89 | KDR (0.38) | KDRAURKBINSRALKKMT2A | |
| SCHEMBL3566624 | 0.88 | AURKB (0.38) | KDRAURKBINSRALKKMT2A | |
| SCHEMBL3575430 | 0.88 | KMT2A (0.50) | KDRAURKBKMT2ABRD4AXL | |
| SCHEMBL2061836 | 0.88 | KDR (0.49) | KDRAURKBINSRALKKMT2A | |
| SCHEMBL2061833 | 0.88 | KDR (0.49) | KDRAURKBINSRALKKMT2A | |
| SCHEMBL2061834 | 0.88 | KDR (0.49) | KDRAURKBINSRALKKMT2A | |
| SCHEMBL3581697 | 0.85 | ULK1 (0.41) | KDRAURKBKMT2AMAPK3 | |
| SCHEMBL2061162 | 0.85 | KDR (0.49) | KDRAURKBINSRALKKMT2A | |
| SCHEMBL2061160 | 0.85 | KDR (0.49) | KDRAURKBINSRALKKMT2A | |
| SCHEMBL2061164 | 0.85 | KDR (0.49) | KDRAURKBINSRALKKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623887-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| US-8623887-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| US-8623887-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| EP-2109605-B1 | 2- [(PHENYLAMINO) -PYRIMIDIN-4YLAMIN0] -CYCLOPENTANE CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF KINASES OF THE CELL CYCLE FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2013-02-20 | — | — | EP | disclosed |
| US-20100144706-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144706-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144706-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| US-20090163467-A1 | New compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090163467-A1 | New compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090163467-A1 | New compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144706-A1 | Compounds | MKI67, CCNA1, CCNT1 | KDR 2478/4885AURKB 1956/4885INSR 122/4885 |
| US-20090163467-A1 | New compounds | CCNA1, MKI67, CCNT1 | KDR 1793/4885AURKB 1454/4885INSR 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.